Allergan and AstraZeneca Commit to Antibiotic Development Deal

According to Genengnews.com, “Dublin-based Allergan has entered into an agreement with AstraZeneca to develop and commercialize a fixed-dose antibiotic formulation currently in Phase II study. The financial terms of the agreement were not detailed, though...

ICYMI: New Drugs Push Pharmaceutical Profits Up

According to an article via SFgate.com, “Revenue from important new medicines for various cancers, hepatitis C and more helped top U.S. drugmakers weather unfavorable currency exchange rates and other challenges. Pfizer Inc., Merck & Co. and Bristol-Myers...